Global research trend in the treatment of the new Coronavirus diseases (COVID-19) : bibliometric analysis.

The Coronavirus 2019 (COVID-19) pandemic has caused worldwide concern and has become a major medical problem. Vaccines and therapeutics are important interventions for the management of this outbreak. This study aims to used bibliometric methods to identify research trends in the domain of therapeutics and vaccines to cure patients with COVID-19 since the beginning of the pandemic. The Web of Science Core Collection database was retrieved for articles on therapeutic approaches to coronavirus disease management published between January 1, 2020 and May 20, 2020. Identified and analyzed the data included title, corresponding author, language, publication time, publication type, research focus. A total of 1569 articles on coronavirus therapeutic means from 84 countries were published in 620 journals. We note the remarkable progressive increase in the number of publications related to research on therapies and vaccines for COVID-19. The United States provided the largest number of articles (405), followed by China (364). Journal of Medical Virology published most of them (n=40). 1005 (64.05%) were articles, 286 (18.23%) were letters, 230 (14.66%) were reviews. The terms "COVID- 19" or "SARS-CoV-2" or "Coronavirus" or "hydroxychloroquine" or "chloroquine" or "2019-nCOV" or "ACE2" or "treatment" or "remdesivir" or "pneumonia" were most frequently used, as shown in the density visualization map. A network analysis based on keyword co-occurrence revealed five distinct types of studies: clinical, biological, epidemiological, pandemic management, and therapeutics (vaccines and treatments). COVID-19 is a major disease that has had an impact on international public health at the global level. Several avenues for treatment and vaccines have been explored. Most of them focus on older drugs used to treat other diseases that have been effective for other types of coronaviruses. There is a discrepancy in the results obtained from the studies of the drugs included in this study. Randomized clinical trials are needed to evaluate older drugs and develop new treatment options.

In this section, we investigated the keywords used in the therapeutic management of COVID-1 3 6 19 to discover the hotspot of this topic. The counting of author keywords revealed that the most frequent treatment used as keywords 1 3 8 were hydroxychloroquine (n = 78 repeats), followed by chloroquine (n = 56 repeats),  To visualize the connection network between author keywords, we considered only keywords 1 4 1 with at least 10 cooccurrences and found out that 38 of 1842 keywords were entered into the 1 4 2 network and clustered into 4 groups ( Figure 6). Cluster 1 (red) related to the "coronavirus diseases and its clinical issues", including terms 1 4 4 related to coronavirus, diseases complication and treatment. Cluster 2 (green) could be called "disease epidemiology", and includes terms like 2019- traditional Chinese medicine. This cluster contains 2 major topics: a) the main term "the 1 4 8 disease" which in addition to the above-mentioned terms, but also b) "treatment and vaccine" 1 4 9 which contains terms like vaccine, traditional Chinese medicine, and antiviral. Cluster 3 (blue) related to "COVID-19 drug treatment", with terms like coronavirus diseases 1 5 1 2019, pandemic, chloroquine, hydroxychloroquine, lopinavir, ritonavir, and remdesivir. Cluster 4 (yellow) with terms including drugs, MERS, SARS and therapy. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 14, 2020. . Similarly, the counting of keywords Plus revealed that the most cooccurrence drugs in the 1 5 4 therapeutic management of COVID-19 documents are hydroxychloroquine (n = 49 repeats) 1 5 5 and chloroquine (n = 45 repeats).

5 6
To visualize the connection network between author keywords, we considered only keywords 1 5 7 with at least 10 cooccurrences and found out that 73 of 871 keywords were entered into the  Cluster 1 (red) related to the "The virus and its biology", including terms related to SARS 1 6 0 virus and their biology. Within this cluster, we found the topic of "virus biology", which 1 6 1 included terms like glycoproteins, antibodies, viral structure, and viral replication. Cluster 2 (green) relates to "The virus and pandemic management", and include topics related 1 6 3 to coronavirus and to pandemic, the disease outbreak and treatment management. Within this 1 6 4 cluster, we found the topic of "care management", which included terms on practice 1 6 5 guidelines and clinical laboratory techniques. Further, within this cluster, we found the topic 1 6 6 of "treatment management", which included terms like viral vaccine, related to Chinese 1 6 7 traditional medicine, and drug development. Cluster 3 (blue) related to "drug treatment", with terms like antiviral agents, chloroquine, 1 6 9 hydroxychloroquine, lopinavir, ritonavir, drug repositioning, drug discovery and drug Cluster 4 (yellow) related to "Clinical epidemiology", with terms relating to age, gender, and 1 7 2 procedures (like x-ray, CT, viral load).  Table 6 presents the 20 most cited articles in the field of therapeutic management of COVID- 19. The number of citations ranged from 23 to 179, with an average citation per item of 55.6. 1 7 6 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 14, 2020. . These top 20 documents received the most citations among all documents (1112 times which 1 7 7 comprise almost 47.76% of all citations). These documents consisted of 10 original articles, 3 1 7 8 letters, 4 reviews, 2 editorial, and 1 diagnostic criteria/guidelines. All the documents were published since the beginning of the pandemic revealed that the total number of articles has 1 9 0 steadily increased significantly since April. An average of 14 papers has been published per 1 9 1 day since the first publication. An increase in research output has also been shown in similar 1 9 2 research related to . The largest proportion of articles in this area came from developed countries, including 1 9 4 United States, followed by China, Italy, the United Kingdom and France. These countries, COVID-19 on 20 May 2020 (https://covid19.who.int/). Possible explanations for these 1 9 7 findings may be rapid economic growth or the progress of scientific research systems in these . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10. 1101/2020 which found that the economic growth of a country affected the quantity of research  article and can also be used to identify research trends in a particular domain. Therefore, 2 0 4 VOSviewer was used to analyze keywords from the work selected in this study that could be  The influential articles identified in this study explored several approaches to combat the new in a meta-analysis found that there is no clinical evidence that corticosteroids provide a net and further conclude that corticosteroid treatment should not be used for the treatment of lung  several FDA-approved drugs, including ribavirin, penciclovir, nitazoxanide, nafamostat, 2 2 3 chloroquine, and two well-known broad-spectrum antiviral drugs, remdesivir (GS-5734) and 2 2 4 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 14, 2020. [19] observed no benefit with lopinavir-ritonavir treatment beyond standard care by 2 3 5 randomizing adult in patients with severe COVID-19 in a 1:1 ratio to receive either lopinavir-2 3 6 ritonavir in addition to standard care or standard care alone [19]. The third most cited article Our study has the advantage of being the first to provide a bibliometric overview of the search 2 4 1 for therapeutic means to cure COVID-19. We have done our best to include all potential 2 4 2 articles. Nevertheless, some limitations inherent to bibliometric analysis may be unavoidable.

4 3
The database is continuously updated, and we have only selected literature from January 1, increase rapidly with the breakthrough of future research. In addition, it appears that some missed. Some people may object to the use of Web of Sciences for data retrieval. However, 2 4 8 we still believe that such a large amount of macroeconomic data and such a detailed analysis 2 4 9 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.13.20122762 doi: medRxiv preprint of the literature are sufficient to represent the trend of development in this area of research.

5 0
Finally, we believe that researchers can ignore a minute number of potentially missing 2 5 1 publications and that our results are sufficient to represent trends in this field. In conclusion, this study used bibliometric methods to identify research trends in the domain Medicine and the International Journal Of Antimicrobial Agents (5) the terms "COVID-19" 2 6 2 or "SARS-CoV-2" or "Coronavirus" or "hydroxychloroquine" or "chloroquine" or "2019-2 6 3 nCOV" or "ACE2" or "treatment" or "remdesivir" or "pneumonia" were most frequently used, pandemic management, and therapeutics (vaccines and treatments). No funding was received for writing this study.
CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 14, 2020. The authors declare that they have no conflicts of interest.

7 4
Ethics approval and consent to participate The analysis in this study is based on a retrospective bibliometric technique; therefore, no 2 7 6 ethical approval was required.                is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 14, 2020. .          . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.13.20122762 doi: medRxiv preprint  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 14, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 14, 2020. .

CC-BY 4.0 International license
It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 14, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 14, 2020. .